title: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
abstract: OBJECTIVE
  The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,450 melanoma patients from their databases in order to validate this staging proposal.
  
  
  METHODS
  There were 17,600 melanoma patients with complete clinical, pathologic, and follow-up information. Factors predicting melanoma-specific survival rates were analyzed using the Cox proportional hazards regression model. Follow-up survival data for 5 years or longer were available for 73% of the patients.
  
  
  RESULTS
  This analysis demonstrated that (1) in the T category, tumor thickness and ulceration were the most powerful predictors of survival, and the level of invasion had a significant impact only within the subgroup of thin (< or = 1 mm) melanomas; (2) in the N category, the following three independent factors were identified: the number of metastatic nodes, whether nodal metastases were clinically occult or clinically apparent, and the presence or absence of primary tumor ulceration; and (3) in the M category, nonvisceral metastases was associated with a better survival compared with visceral metastases. A marked diversity in the natural history of pathologic stage III melanoma was demonstrated by five-fold differences in 5-year survival rates for defined subgroups. This analysis also demonstrated that large and complex data sets could be used effectively to examine prognosis and survival outcome in melanoma patients.
  
  
  CONCLUSIONS
  The results of this evidence-based methodology were incorporated into the AJCC melanoma staging as described in the companion publication.
authors.affiliation: Johns Hopkins Medical Institutions, Baltimore, MD, USA. balchc@asco.org
authors.forename: C M
authors.initials: CM
authors.lastname: Balch
authors.forename: S J
authors.initials: SJ
authors.lastname: Soong
authors.forename: J E
authors.initials: JE
authors.lastname: Gershenwald
authors.forename: J F
authors.initials: JF
authors.lastname: Thompson
authors.forename: D S
authors.initials: DS
authors.lastname: Reintgen
authors.forename: N
authors.initials: N
authors.lastname: Cascinelli
authors.forename: M
authors.initials: M
authors.lastname: Urist
authors.forename: K M
authors.initials: KM
authors.lastname: McMasters
authors.forename: M I
authors.initials: MI
authors.lastname: Ross
authors.forename: J M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: M B
authors.initials: MB
authors.lastname: Atkins
authors.forename: J A
authors.initials: JA
authors.lastname: Thompson
authors.forename: D G
authors.initials: DG
authors.lastname: Coit
authors.forename: D
authors.initials: D
authors.lastname: Byrd
authors.forename: R
authors.initials: R
authors.lastname: Desmond
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: G H
authors.initials: GH
authors.lastname: Lyman
authors.forename: A
authors.initials: A
authors.lastname: Morabito
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000592:standards*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012878:Skin Neoplasms / Q000401:mortality* / Q000556:secondary*; D016019:Survival Analysis; D014481:United States / Q000453:epidemiology